$ZBH (Zimmer Biomet Holdings, Inc.)

$ZBH {{ '2016-07-28T18:32:03+0000' | timeago}} • Webcast

$ZBH said in 2Q16 hip revenues grew 8.1% in the Asia Pacific region, 3.6% in Europe, Middle East & Africa, and 1.5% in the Americas compared to the prior year quarter. The company plans to further deliver hip growth in 2H16, backed by a diversified portfolio of solutions that address a broad spectrum of clinical challenges and surgical approaches.

$ZBH {{ '2017-08-08T13:03:16+0000' | timeago}} • Announcement

$ZBH's BoD declared a 3Q17 cash dividend of $0.24 per share. The dividend will be paid on Oct. 27, 2017 to stockholders of record on Sept. 22, 2017.

$ZBH {{ '2017-06-13T11:32:43+0000' | timeago}} • Announcement

Medical device company $ZBH announced that the U.S. FDA has notified the company about the closing out of its warning letter dated June 3, 2015 relating to its Zhejiang, China manufacturing facility. The company added that it will continue to take the necessary actions towards stricter quality control and regulatory compliance going forward.

$ZBH {{ '2017-05-30T21:28:38+0000' | timeago}} • Announcement

$ZBH's Board of Directors approved the payment of a quarterly cash dividend to stockholders for 2Q17. The cash dividend of $0.24 per share will be paid on or about July 28, 2017 to stockholders of record on June 23, 2017.

$ZBH {{ '2017-03-01T15:01:11+0000' | timeago}} • Announcement

$ZBH BoD has approved a quarterly cash dividend for 1Q17. The dividend of $0.24 per share will be paid on or about April 28, 2017 to stockholders of record as on March 31, 2017.

$ZBH {{ '2017-02-02T16:22:10+0000' | timeago}} • Announcement

$ZBH said the U.S. Food and Drug Administration (FDA) approved an expanded 26-week efficacy claim for its single-injection viscosupplement Gel-One Cross-linked Hyaluronate for the treatment of knee pain associated with osteoarthritis.

$ZBH {{ '2017-01-31T17:58:23+0000' | timeago}} • Webcast

During 4Q16, $ZBH continued to make progress towards enhancing and improving its supply chain and manufacturing and quality systems. The company anticipates continued progress towards the replenishment of safety stocks on key cross-sell products throughout 1H17, which will accelerate top line growth during 2H17.

$ZBH {{ '2017-01-31T17:50:45+0000' | timeago}} • Webcast

Healthcare company $ZBH said that it has made strategic investments throughout 2016 to broaden and diversify its musculoskeletal portfolio, including the introduction of more than 50 new clinical technology solutions and services.

$ZBH {{ '2017-01-31T15:39:40+0000' | timeago}} • Announcement

$ZBH expects constant currency revenue for FY17 to increase by approx. 3.7-4.7%. $ZBH expects foreign currency translation to decrease revenues by approx. 1.5%.  Therefore, revenue is expected to be in a range of $7.855-7.930Bil. The Company expects its FY17 diluted EPS to be in a range of $4.37-4.67.

$ZBH {{ '2017-01-31T15:35:34+0000' | timeago}} • Announcement

$ZBH reported lower 4Q16 earnings. Net earnings during the quarter fell 47.5% to $66.6MM from $127MM during 4Q15. Diluted EPS fell 46.8% to $0.33 from $0.62 during 4Q15. Net sales rose 4.1% YoverY to $2Bil. Excluding items, $COH earned $2.14 per share.

$ZBH {{ '2017-01-17T13:23:47+0000' | timeago}} • Announcement

$ZBH implemented a leadership transition that capitalizes on the strength of the its management team. Effective Jan. 23, 2017, Robert Delp will assume the position of President, Americas and join the executive leadership team of the company. Stuart Kleopfer has decided to retire from his position as President, Americas.

$ZBH {{ '2017-01-12T20:36:06+0000' | timeago}} • Announcement

$ZBH concluded agreements with the U.S. Department of Justice and the U.S. Securities and Exchange Commission to resolve the U.S. Foreign Corrupt Practices Act (FCPA) matters involving Biomet as well as in relation to former deferred prosecution agreement and consent to final judgment that Biomet entered into with DOJ and SEC, on March 26, 2012.

$ZBH {{ '2017-01-10T13:09:46+0000' | timeago}} • Announcement

$ZBH expects 2016 net sales of $7.684Bil, up 28.1% from last year. On an adjusted constant currency basis, $ZBH sees revenue to increase by 3.4%. Excluding contribution from the LDR Holding transaction, revenue rose by 2.3% on an adjusted constant currency basis. $ZBH now sees adjusted EPS to be towards upper end of prior estimate of $7.90-7.95.

$ZBH {{ '2017-01-10T13:06:47+0000' | timeago}} • Announcement

$ZBH expects 4Q16 net sales of about $2.013Bil, an increase of 4.1% over last year. On adjusted constant currency basis, revenue increased by 4.4%. Excluding the contribution from the LDR transaction and adjusting for one less billing day in the quarter, $ZBH estimates that revenues increased 3.5% over 4Q15.

$ZBH {{ '2016-12-19T12:45:06+0000' | timeago}} • Announcement

$ZBH BoD approved a quarterly cash dividend for 4Q16 of $0.24 per share, payable on or about Jan. 27, 2017 to stockholders of record as of the close of business on Dec. 30, 2016.

$ZBH {{ '2016-12-06T20:15:45+0000' | timeago}} • Announcement

$ZBH priced an offering of EUR 500MM of its 1.414% senior unsecured notes due 2022 and EUR 500MM of 2.425% senior unsecured notes due 2026. The closing is expected to occur on Dec. 13, 2016. The notes will pay interest on an annual basis. The joint book-running managers for the offering are BNP Paribas, HSBC Bank plc and RBC Europe Limited.

$ZBH {{ '2016-11-21T15:54:52+0000' | timeago}} • Announcement

$ZBH commences cash tender offers for up to $1.1Bil aggregate of its 5.75% senior notes due 2039, its 4.45% senior notes due 2045, its 4.25% senior notes due 2035, its 3.55% senior notes due 2025 and its 4.625% senior notes due 2019. The purpose of the offers is to reduce the principal amount of the company's outstanding debt securities.

$ZBH {{ '2016-11-15T17:57:59+0000' | timeago}} • Announcement

$ZBH announced positive update on biologics pipeline following preliminary analysis of data from the first pivotal trial of stem cell therapy for critical limb ischemia to reach completion. The trial is the first pivotal study of its kind to complete enrollment and 1-year follow-up in a challenging patient population with a high mortality risk.

$ZBH {{ '2016-10-31T12:34:43+0000' | timeago}} • Webcast

$ZBH's knee business was flat on a global basis in 3Q16, reflecting positive volume and mix of 1.9% and negative price of 2%. Hip business grew by 0.6%, reflecting positive volume and mix of 3% and negative price of 2.4%.

$ZBH {{ '2016-10-31T12:31:22+0000' | timeago}} • Webcast

$ZBH said it expects 4Q16 revenue to be in the range of $1,960-1,980MM. Adjusted diluted EPS is expected to be in the range of $2.08-2.13 per share.

$ZBH {{ '2016-10-31T11:51:50+0000' | timeago}} • Announcement

$ZBH estimates FY16 revenue to be in the range of $7.630-7.650Bil, up about 27% on a reported basis, from a year ago. FY16 diluted EPS is expected to be in the range of $1.50-1.60, and $7.90-7.95 on an adjusted basis.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
INFO (IHS Markit Ltd.)
Tuesday, September 26 2017 - 12:00pm
AOBC (American Outdoor Brands Corporation)
Thursday, September 7 2017 - 9:00pm
HOME (At Home Group Inc.)
Tuesday, September 5 2017 - 8:30pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
ATHX (Athersys, Inc.)
Wednesday, August 9 2017 - 8:30pm
XRAY (DENTSPLY International Inc.)
Wednesday, August 9 2017 - 12:30pm
VCEL (Vericel Corporation)
Wednesday, August 9 2017 - 12:00pm
STE (Steris Plc)
Tuesday, August 8 2017 - 2:00pm
BIVV (Bioverativ Inc.)
Thursday, August 3 2017 - 12:00pm
VVV (Valvoline Inc.)
Wednesday, August 2 2017 - 3:00pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, August 1 2017 - 12:30pm
ITGR (Integer Holdings Corporation)
Thursday, July 27 2017 - 9:00pm
NUVA (NuVasive, Inc.)
Thursday, July 27 2017 - 8:30pm
FTI (TechnipFMC plc)
Thursday, July 27 2017 - 12:00pm
ZBH (Zimmer Biomet Holdings, Inc.)
Thursday, July 27 2017 - 12:00pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, July 26 2017 - 12:30pm
AMD (Advanced Micro Devices, Inc.)
Tuesday, July 25 2017 - 9:00pm
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
AOBC (American Outdoor Brands Corporation)
Thursday, June 29 2017 - 9:00pm

AlphaGraphics you may like